Seegene Highlights Advanced HPV Solutions at EUROGIN 2025 Conference in Portugal

Seegene Unveils Innovative HPV Genotyping Solutions at EUROGIN 2025

Seegene Inc., a pioneer in PCR molecular diagnostics, made a significant impact at the EUROGIN 2025 congress held in Porto, Portugal, from March 16-19. The conference, which is a prominent event focused on multidisciplinary approaches to HPV, allowed Seegene to unveil its high-precision Human Papillomavirus (HPV) screening and full genotyping solutions aimed at enhancing the accuracy of cervical cancer diagnoses.

A Commitment to Accurate HPV Detection

At the congress, Seegene presented its latest HPV diagnostic product lineup, designed to simultaneously detect multiple HPV genotypes that can lead to cervical cancer and other HPV-related conditions. This multi-faceted approach is crucial for identifying high-risk HPV types known to contribute to cervical cancer, as well as detecting genotypes associated with benign tumors, thereby improving overall screening outcomes.

Themed “Elevating Confidence in HPV Screening,” Seegene's exhibition booth showcased the company’s commitment to advancing HPV diagnostics. The organization also hosted symposium programs where leading clinical experts from Europe discussed various strategies for integrating HPV testing into routine clinical practice. The importance of continuous improvement in HPV testing and screening methods was a central theme at the symposium.

The Role of Self-Sampling in HPV Screening

One of the most notable topics highlighted was the concept of self-sampling for HPV testing. This innovative approach allows individuals to collect their own samples, which has shown to not only simplify the testing process but also promote more widespread adoption of HPV screening among women. Daniel Shin, Seegene's Executive Vice President noted, “Self-sampling can significantly increase the accessibility of HPV testing, facilitating timely and effective cervical cancer screening.”

The discussion emphasized that reliable HPV testing is critical for early intervention in cervical cancer cases, which can dramatically affect patient outcomes.

Seegene's Commitment to Global Health Initiatives

Seegene’s presence at EUROGIN demonstrates its ongoing commitment to improving HPV screening and prevention strategies worldwide. The company’s innovative solutions aim to meet the goals set by the World Health Organization (WHO), which highlighted the urgent need to eliminate cervical cancer as a public health problem. The WHO's 90-70-90 campaign focuses not only on increasing HPV vaccination but also on ensuring high-performance screening and treatments for women diagnosed with pre-cancerous conditions or invasive cancers.

Echoing this sentiment, Seegene has previously participated in significant events such as the Asia-Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) 2024 in Seoul, advocating for advanced measures in HPV prevention and management.

Seegene's Legacy in PCR Technology

With over two decades of experience in R&D, manufacturing, and business related to syndromic real-time PCR technologies, Seegene has established itself as a leader in the molecular diagnostics arena. The company gained global recognition during the COVID-19 pandemic by delivering over 340 million diagnostic tests to more than 100 countries, signifying its capability to respond effectively to health crises.

Seegene continues to innovate its syndromic real-time PCR technology, which offers the ability to detect multiple pathogens simultaneously within a single test. This technology is pivotal in enhancing diagnostic capabilities across various medical conditions, not just HPV.

As Seegene moves forward from EUROGIN 2025, its focus remains sharp on advancing HPV screening and improving diagnostic precision for better health outcomes worldwide. For more information about Seegene's products and ongoing initiatives, visit Seegene.com or follow their updates on LinkedIn.